This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Korea Institute of Science and Technology. Active years: 2013-2016.
Company Filing History:
Years Active: 2013-2016
Title: Sojin Lee - Innovator in Tumor-Targeted Delivery Systems
Introduction
Sojin Lee is a prominent inventor based in Seoul, South Korea. She has made significant contributions to the field of biomedical engineering, particularly in the development of innovative delivery systems for therapeutic agents. With a total of 2 patents, her work focuses on enhancing the efficacy of siRNA delivery for cancer treatment.
Latest Patents
Sojin Lee's latest patents include a gelatin-based nanoparticle complex designed for tumor-targeted delivery of siRNA. This complex is engineered to facilitate specific gene silencing in tumor cells. The formulation consists of poly-siRNA chains modified with thiol groups and thiolated gelatin, which are linked through disulfide crosslinking and charge interactions. This innovative system is resistant to degradation in the bloodstream and allows for efficient absorption into tumor cells without causing cytotoxicity. The siRNA delivered through this method effectively silences target gene expression.
Another notable patent is the human serum albumin-siRNA nano-sized carrier system. This system features siRNA bound to human serum albumin, which is stabilized by a biodegradable covalent bond. This design enhances the delivery efficiency of siRNA to target sites within the body, particularly cancer tissues. The ability to administer this carrier system at relatively low concentrations broadens its potential applications in various therapeutic contexts.
Career Highlights
Sojin Lee is affiliated with the Korea Institute of Science and Technology, where she continues to advance her research in drug delivery systems. Her innovative approaches have garnered attention in the scientific community, contributing to the ongoing development of effective cancer therapies.
Collaborations
Throughout her career, Sojin Lee has collaborated with esteemed colleagues, including Ick Chan Kwon and Kwangmeyung Kim. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of her research.
Conclusion
Sojin Lee's work in the field of tumor-targeted delivery systems exemplifies the potential of innovative approaches in cancer treatment. Her patents reflect a commitment to improving therapeutic efficacy and patient outcomes. The advancements she has made in siRNA delivery systems are paving the way for future breakthroughs in medical science.